Janux Therapeutics, Inc. (JANX)Healthcare | Biotechnology | San Diego, United States | NasdaqGM
15.82 USD
+0.63
(4.147%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 15.51 -0.31 (-0.310%) ⇩ (April 17, 2026, 6:13 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:51 p.m. EDT
JANX is a high-risk, high-reward stock with a volatile price history and mixed analyst sentiment. The recent price action shows a range-bound movement, with no clear trend. The company's fundamentals are weak, with negative earnings and high overall risk. While there are some positive news headlines, the stock's recent performance and the lack of a consistent dividend make it unsuitable for short-term trading or long-term holding. Investors should consider the high volatility and the uncertain future prospects before making any investment decisions. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.052130 |
| AutoETS | 0.064543 |
| AutoARIMA | 0.064543 |
| AutoTheta | 0.065280 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.40 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.381 |
| Excess Kurtosis | -1.00 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.314 |
| Revenue per Share | 0.161 |
| Market Cap | 962,356,800 |
| Forward P/E | -4.67 |
| Beta | 2.81 |
| Website | https://www.januxrx.com |
As of April 11, 2026, 3:51 p.m. EDT: Options activity suggests a mixed sentiment. The ATM strikes are showing some interest, with elevated IV in some expirations, indicating possible volatility expectations. However, the overall positioning is skewed towards OTM calls and puts, which may imply uncertainty about the short-term direction. The presence of higher IV on certain strikes, particularly for out-of-the-money calls, could indicate speculation on a potential upward move, while the puts suggest caution or hedging against downside risk.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.48156995 |
| Address1 | 10,955 Vista Sorrento Parkway |
| Address2 | Suite 200 |
| All Time High | 71.71 |
| All Time Low | 5.65 |
| Ask | 15.87 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 868,740 |
| Average Daily Volume3 Month | 1,218,796 |
| Average Volume | 1,218,796 |
| Average Volume10Days | 868,740 |
| Beta | 2.812 |
| Bid | 15.77 |
| Bid Size | 1 |
| Board Risk | 7 |
| Book Value | 15.846 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 15.82 |
| Current Ratio | 39.04 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 15.85 |
| Day Low | 15.33 |
| Debt To Equity | 2.314 |
| Display Name | Janux Therapeutics |
| Earnings Timestamp | 1,772,139,600 |
| Earnings Timestamp End | 1,778,184,000 |
| Earnings Timestamp Start | 1,778,184,000 |
| Ebitda | -155,638,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.115 |
| Enterprise To Revenue | 1.793 |
| Enterprise Value | 17,928,798 |
| Eps Current Year | -2.38948 |
| Eps Forward | -3.38843 |
| Eps Trailing Twelve Months | -1.83 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 13.8535 |
| Fifty Day Average Change | 1.9664993 |
| Fifty Day Average Change Percent | 0.14194964 |
| Fifty Two Week Change Percent | -48.156994 |
| Fifty Two Week High | 35.34 |
| Fifty Two Week High Change | -19.52 |
| Fifty Two Week High Change Percent | -0.5523486 |
| Fifty Two Week Low | 12.12 |
| Fifty Two Week Low Change | 3.6999998 |
| Fifty Two Week Low Change Percent | 0.3052805 |
| Fifty Two Week Range | 12.12 - 35.34 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,623,418,200,000 |
| Float Shares | 41,680,634 |
| Forward Eps | -3.38843 |
| Forward P E | -4.6688285 |
| Free Cashflow | -51,267,876 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 109 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -115,896,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06916 |
| Held Percent Institutions | 1.05082 |
| Implied Shares Outstanding | 60,831,656 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-06-11 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. |
| Long Name | Janux Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 962,356,800 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_676965261 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -113,625,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 962,356,797 |
| Number Of Analyst Opinions | 16 |
| Open | 15.33 |
| Operating Cashflow | -82,235,000 |
| Operating Margins | -15.766701 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 858 751 4493 |
| Post Market Change | -0.30999947 |
| Post Market Change Percent | -1.9595416 |
| Post Market Price | 15.51 |
| Post Market Time | 1,776,463,990 |
| Previous Close | 15.19 |
| Price Eps Current Year | -6.620687 |
| Price Hint | 2 |
| Price To Book | 0.9983592 |
| Price To Sales Trailing12 Months | 96.23568 |
| Profit Margins | 0.0 |
| Quick Ratio | 38.924 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.41176 |
| Region | US |
| Regular Market Change | 0.63 |
| Regular Market Change Percent | 4.14747 |
| Regular Market Day High | 15.85 |
| Regular Market Day Low | 15.33 |
| Regular Market Day Range | 15.33 - 15.85 |
| Regular Market Open | 15.33 |
| Regular Market Previous Close | 15.19 |
| Regular Market Price | 15.82 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 1,120,720 |
| Return On Assets | -0.09553 |
| Return On Equity | -0.1148 |
| Revenue Per Share | 0.161 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 60,831,656 |
| Shares Percent Shares Out | 0.1273 |
| Shares Short | 7,744,629 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 9,996,191 |
| Short Name | Janux Therapeutics, Inc. |
| Short Percent Of Float | 0.18200001 |
| Short Ratio | 6.68 |
| Source Interval | 15 |
| State | CA |
| Symbol | JANX |
| Target High Price | 100.0 |
| Target Low Price | 15.0 |
| Target Mean Price | 51.25 |
| Target Median Price | 45.0 |
| Total Cash | 966,566,976 |
| Total Cash Per Share | 15.889 |
| Total Debt | 22,139,000 |
| Total Revenue | 10,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.83 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 20.3194 |
| Two Hundred Day Average Change | -4.499401 |
| Two Hundred Day Average Change Percent | -0.22143374 |
| Type Disp | Equity |
| Volume | 1,120,720 |
| Website | https://www.januxrx.com |
| Zip | 92,130 |